Skip to Main Content

A new federal effort is underway to keep biopharmaceutical manufacturing stateside — and scale up the production of complex biological drugs.

A new high-tech trade group, dubbed NIIMBL — the pithy shorthand for the National Institute for Innovation in Manufacturing Biopharmaceuticals — on Friday received $70 million from the Department of Commerce. On top of that, NIIMBL will be getting another $129 million from a public-private consortium of 150 companies, academic institutions, and nonprofits, as well as 25 states.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED